LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Torin1 | 0.12 | uM | LJP6 | 3 | O17 | 72 | hr | 1401 | 1742 | 4223 | 0.4125 | 0.1207 |
| SK-BR-3 | Torin2 | 0.12 | uM | LJP5 | 1 | I23 | 72 | hr | 1401 | 1226 | 4223 | 0.2903 | -0.0622 |
| SK-BR-3 | Torin2 | 0.12 | uM | LJP5 | 2 | I23 | 72 | hr | 1401 | 1450 | 4223 | 0.3434 | 0.0172 |
| SK-BR-3 | Torin2 | 0.12 | uM | LJP5 | 3 | I23 | 72 | hr | 1401 | 1254 | 4223 | 0.2969 | -0.0523 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 1 | B17 | 72 | hr | 1401 | 1248 | 4223 | 0.2955 | -0.0544 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 2 | B17 | 72 | hr | 1401 | 1315 | 4223 | 0.3114 | -0.0307 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 3 | B17 | 72 | hr | 1401 | 1375 | 4223 | 0.3256 | -0.0094 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 1 | P23 | 72 | hr | 1401 | 2877 | 4223 | 0.6813 | 0.5229 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 2 | P23 | 72 | hr | 1401 | 3256 | 4223 | 0.7710 | 0.6573 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 3 | P23 | 72 | hr | 1401 | 3663 | 4223 | 0.8674 | 0.8015 |
| SK-BR-3 | TWS119 | 0.12 | uM | LJP5 | 1 | M05 | 72 | hr | 1401 | 4159 | 4223 | 0.9848 | 0.9773 |
| SK-BR-3 | TWS119 | 0.12 | uM | LJP5 | 2 | M05 | 72 | hr | 1401 | 4431 | 4223 | 1.0492 | 1.0737 |
| SK-BR-3 | TWS119 | 0.12 | uM | LJP5 | 3 | M05 | 72 | hr | 1401 | 4827 | 4223 | 1.1430 | 1.2140 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 1 | C17 | 72 | hr | 1401 | 4107 | 4223 | 0.9725 | 0.9589 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 2 | C17 | 72 | hr | 1401 | 4621 | 4223 | 1.0942 | 1.1410 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 3 | C17 | 72 | hr | 1401 | 4296 | 4223 | 1.0173 | 1.0258 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP5 | 1 | G17 | 72 | hr | 1401 | 4183 | 4223 | 0.9905 | 0.9858 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP5 | 2 | G17 | 72 | hr | 1401 | 4574 | 4223 | 1.0831 | 1.1244 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP5 | 3 | G17 | 72 | hr | 1401 | 4792 | 4223 | 1.1347 | 1.2016 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP6 | 1 | G17 | 72 | hr | 1401 | 3621 | 4223 | 0.8574 | 0.7866 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP6 | 2 | G17 | 72 | hr | 1401 | 3798 | 4223 | 0.8993 | 0.8493 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP6 | 3 | G17 | 72 | hr | 1401 | 3746 | 4223 | 0.8870 | 0.8309 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 1 | L11 | 72 | hr | 1401 | 1687 | 4223 | 0.3995 | 0.1012 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 2 | L11 | 72 | hr | 1401 | 1546 | 4223 | 0.3661 | 0.0512 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 3 | L11 | 72 | hr | 1401 | 1714 | 4223 | 0.4059 | 0.1107 |